1. Adams K, Rhoads JP, Surie D, et al. Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study. BMJ 2022;379:e072065 doi:10.1136/bmj-2022-072065
2. Doheny K. New COVID Omicron Boosters About to Arrive, With Some Controversy. Medscape. 2022. https://www.medscape.com/viewarticle/980055
3. The U.S. Food and Drug Administration. COVID-19 Vaccines. 2022. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines#authorized-vaccines
4. The U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Moderna and Pfizer-BioNTech Bivalent COVID-19 Vaccines for Use as a Booster Dose in Younger Age Groups. 2022. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-and-pfizer-biontech-bivalent-covid-19-vaccines
5. Burki T. COVID vaccine booster doses for omicron variants. Lancet Respir Med. 2022;10(10):936. doi:10.1016/S2213-2600(22)00361-7
6. Pedersen RM, Bang LL, Madsen LW, et al. Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination. Emerg Infect Dis. 2022;28(6):1274-1275. doi:10.3201/eid2806.220503
7. Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, McGhee N, Tomassini JE, Chen X, Chang Y, Sutherland A, Montefiori DC, Girard B, Edwards DK, Feng J, Zhou H, Baden LR, Miller JM, Das R. A Bivalent Omicron-Containing Booster Vaccine against Covid-19. N Engl J Med. 2022 Oct 6;387(14):1279-1291. doi: 10.1056/NEJMoa2208343. Epub 2022 Sep 16. PMID: 36112399; PMCID: PMC9511634.
8. Fang Z, Monteiro VS, Hahn AM, et al. Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5. Cell Discov. 2022 Oct 11;8(1):108. doi: 10.1038/s41421-022-00473-4.
9. Agrawal U, Bedston S, McCowan C, et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. Lancet. 2022;400(10360):1305-1320. doi:10.1016/S0140-6736(22)01656-7